Detail akcie Kala Pharmactcls Rg online

Business Summary: KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, KALA BIO Inc revenues was not reported. Net loss decreased 9% to $27.7M. Lower net loss reflects Fair Value Adjustments on Other Assets decrease from $549K (expense) to $4.7M (income), Interest expense decrease of 29% to $3.1M (expense), General and administrative - Balancing decrease of 6% to $9.3M (expense).